#EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow

BE COMPLETE RCT Bimekizumab vs. PBO in TNFiIR PsA pts meets its primary criteria at 16wks w/ -ACR50 43% -PASI 90 69% and MDA achieved in 40+% pts No new safety signal. @RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc

Merola et al. IL23i Risankizumab in PsA. Proportion achieving ACR20 week24 by subgroup. Effective across all groups. Similar irrespective of demographics, disease characteristics, concomittent meds, prior bDMARD use. @RheumNow #EULAR2022 POS1032 https://t.co/GAVKFpwCst

FAP tracer-based PET-CT ☄️ (68Ga-FAPI-04) ⚡️Detects metabolic activity and tissular inflammation ⚡️Correlates with MRI changes in PsA ⚡️Is associated w/ progression of joint damage ⚡️Is sensitive to change An exciting new imaging modality! @RheumNow OP0256 #EULAR2022 https://t.co/16Z1R71YjC

Risk of haematological malignancy in PsA Nordic cohorts *40 events, IR 67/100 000 person-years *NO difference between PsA bionaive and TNFi treated BUT *⬆️ in PsA vs. matched controls *no difference between myeloid and lymphoid malignancies. OP0257 #EULAR2022 @RheumNow https://t.co/oIojobgDP3

Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh

Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose): ⭐️ACR50 52% ⭐️PASI 90 50% ⭐️Resolution of enthesitis LEI 88% ⭐️Safety profile similar to what observed in PsO. Promising for the enthesitis domain! @RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP

Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb